Endo Acquires Johnson Matthey’s Oxymorphone Patent
CHADDS FORD, Pa., March 22, 2012 /PRNewswire/ — Endo (Nasdaq: ENDP) announced today that it has acquired U.S. patent 7,851,482 B2 for oxymorphone hydrochloride, the key API in all formulations of OPANA, from Johnson Matthey plc. Johnson Matthey is a leading supplier of active pharmaceutical ingredients through its worldwide Fine Chemicals Division.
By acquiring Johnson Matthey’s patent to the oxymorphone ingredient, which will be listed in the U.S. Food and Drug Administration’s Orange Book, Endo will enjoy additional patent protection for its OPANA franchise, now through 2029.
“This patent not only covers our newly designed to be crush resistant OPANA® ER, it covers all products that include oxymorphone that are manufactured in accordance with current FDA specifications,” said Julie McHugh, chief operating officer of Endo.
Endo Pharmaceuticals Holdings Inc. (Endo) is a US-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through our operating companies: AMS, Endo Pharmaceuticals, HealthTronics and Qualitest, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike. Learn more at www.endo.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.